Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia

AIDS

Volumn 25, Issue 17, 2011, Pages 2167-2175

  Peterson, Ingrid ^a   Togun, Oluwatoyin ^b   De Silva, Thushan ^a,c,d   Oko, Francis ^b   Rowland Jones, Sarah ^d   Jaye, Assan ^b,e   Peterson, Kevin ^b,f  

^a Swaziland HIV Incidence Measurement Survey ^*  (United States)

^b Medical Research Council (UK) the Gambia Unit   (Gambia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Africa; Antiretroviral therapy; HIV 2; Mortality; Risk factors

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GAMBIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROLOGY;

EID: 80055042755     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834c4adb     Document Type: Article

References (48)

1. UNAIDS. Global Report on AIDS. New York: UNAIDS; 2008.
2. WHO. Towards universal access: scaling up priority in the health sector. Progress report 2008. Geneva: World Health Organization; 2008.
3. Surveillance UWWGoGHAaS. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiology and response for The Gambia. New York: UNAIDS; 2008.
4. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
5. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008:8.
6. Basset IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135-139.
7. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008; 24:555-560. (Pubitemid 351571039)
8. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2006.
9. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:1691-1700.
10. National AIDS Secretariat of The Gambia UUCPR-TGIU.
11. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455-1458. (Pubitemid 43948255)
12. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget M, Bouchez J, et al. Antiretroviral therapy in HIV-2- infected patients: changes in plasma viral load, CD4R cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17:S49-S54. (Pubitemid 36951669)
13. Sarfo FS, Bibby DF, Schwab U, Appiah LT, Clark DA, Collini P, et al. Inadvertent nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. J Antimicrob Chemother 2009; 64:667-669.
14. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-468. (Pubitemid 351317287)
15. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009; 48:476-483.
16. Drylewicz J, Eholie S, Maiga M, Zannou DM, Sow PS, Ekouevi DK, et al. First-year lymphocyte T CD4R response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010; 24:1043-1050.
17. Harries K, Zachariah R, Manzi M, Firmenich P, Mathela R, Drabo J, et al. Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. Trans R Soc Trop Med Hyg 2010; 104:154-161.
18. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16:1775-1783.
19. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998; 1:457-468. (Pubitemid 128543591)
20. Berry N, Ariyoshi K, Jobe O, Ngum PT, Corrah T, Wilkins A, et al. HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4Rlymphopenia in HIV type 2-infected individuals. AIDS Res Hum Retroviruses 1994; 10:1031-1037. (Pubitemid 24279175)
21. Alabi AS, Jaffar S, Ariyoshi K, Blanchard T, Schim van der Loeff M, Awasana AA, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 17:1513-1520. (Pubitemid 36900552)
22. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-882. (Pubitemid 351563837)
23. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009; 47:2200-2208.
24. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-461.
25. Matheron S, Pueyo S, Damond F, Simon S, Lepetre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 2003; 17:2593-2601. (Pubitemid 38402337)
26. Gottlieb GS, Badiane NMD, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource limited West Africa. Clin Infect Dis 2009; 48:476-483.
27. Mullins C, Eisen G, Popper S, Sarr AD, Sankale J, Berger JJ, et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38:1771-1779. (Pubitemid 38781672)
28. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. Good response to lopinavir/ritonavircontaining antiretroviral regimens in antiretroviral-naive HIV-2 infected patients. AIDS 2009; 23:1171-1179.
29. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures: a meta-analysis. Int J STD AIDS 2008; 19:291-296. (Pubitemid 351748268)
30. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
31. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnoud L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360. (Pubitemid 44789538)
32. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 2009; 103:588-593.
33. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khatelitsha, South Africa. AIDS 2004; 18:887-895. (Pubitemid 38553709)
34. Rhamadani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-1 infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-1498. (Pubitemid 351411882)
35. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14:722-731.
36. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS 2011; 25:1189-1197.
37. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008; 8:93.
38. NtemgwaML, Toni TA, BrennerBG, Camacho RJ,WainbergMA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53:3611-3619.
39. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548. (Pubitemid 351522031)
40. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543. (Pubitemid 36578959)
41. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middleincome countries. Lancet 2009; 9:637-649.
42. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088-2091. (Pubitemid 351831850)
43. Hansmann A, Schim van der Loeff MF, Kaye S, Awasana AA, Sarge-Njie R, O'Donovan D, et al. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2- infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr 2005; 38:335-341. (Pubitemid 40333501)
44. Schim van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46.
45. de Silva TI, Turner R, Hue S, Trikha R, van Tienen C, Onyango C, et al. HIV-1 subtype distribution in the Gambia and the significant presence of CRF49-cpx, a novel circulating recombinant form. Retrovirology 2010; 7:82.
46. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 nonsubtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12:11.
47. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
48. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.